Table of Contents
Chapter 1. Global Opioid Induced Constipation (OIC) Drugs Market Executive Summary
1.1. Global Opioid Induced Constipation (OIC) Drugs Market Size & Forecast (2022-2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Drug Type
1.3.2. By Prescription Type
1.3.3. By Distribution Channel
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion
Chapter 2. Global Opioid Induced Constipation (OIC) Drugs Market Definition and Research Assumptions
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Consumer's Perspective)
2.3.4. Demand Side Analysis
2.3.4.1. Regulatory Frameworks
2.3.4.2. Technological Advancements
2.3.4.3. Environmental Considerations
2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates
Chapter 3. Global Opioid Induced Constipation (OIC) Drugs Market Dynamics
3.1. Market Drivers
3.1.1. Increase in Chronic Pain Cases
3.1.2. Rise in Awareness and Education Programs
3.1.3. Growth in Pharmaceutical Innovations
3.2. Market Challenges
3.2.1. Side Effects of OIC Drugs
3.2.2. High Costs and Unfavorable Reimbursement Policies
3.3. Market Opportunities
3.3.1. Emerging Markets and Healthcare Infrastructure
3.3.2. Rising R&D Activities
3.3.3. Increase in Demand for Novel Therapeutics
Chapter 4. Global Opioid Induced Constipation (OIC) Drugs Market Industry Analysis
4.1. Porter's 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter's 5 Force Model
4.1.7. Porter's 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top Investment Opportunity
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Global Opioid Induced Constipation (OIC) Drugs Market Size & Forecasts by Drug Type 2022-2032
5.1. Segment Dashboard
5.2. Global Opioid Induced Constipation (OIC) Drugs Market: Drug Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
5.2.1. Mu-opioid Receptor Antagonists
5.2.2. Chloride Channel-2 Activators
5.2.3. Others
Chapter 6. Global Opioid Induced Constipation (OIC) Drugs Market Size & Forecasts by Prescription Type 2022-2032
6.1. Segment Dashboard
6.2. Global Opioid Induced Constipation (OIC) Drugs Market: Prescription Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
6.2.1. Over The Counter Drugs
6.2.2. Prescribed Drugs
Chapter 7. Global Opioid Induced Constipation (OIC) Drugs Market Size & Forecasts by Distribution Channel 2022-2032
7.1. Segment Dashboard
7.2. Global Opioid Induced Constipation (OIC) Drugs Market: Distribution Channel Revenue Trend Analysis, 2022 & 2032 (USD Billion)
7.2.1. Hospital Pharmacies
7.2.2. Online Providers
7.2.3. Drug Store and Retail Pharmacies
Chapter 8. Global Opioid Induced Constipation (OIC) Drugs Market Size & Forecasts by Region 2022-2032
8.1. North America Opioid Induced Constipation (OIC) Drugs Market
8.1.1. U.S. Opioid Induced Constipation (OIC) Drugs Market
8.1.1.1. Drug Type breakdown size & forecasts, 2022-2032
8.1.1.2. Prescription Type breakdown size & forecasts, 2022-2032
8.1.1.3. Distribution Channel breakdown size & forecasts, 2022-2032
8.1.2. Canada Opioid Induced Constipation (OIC) Drugs Market
8.1.2.1. Drug Type breakdown size & forecasts, 2022-2032
8.1.2.2. Prescription Type breakdown size & forecasts, 2022-2032
8.1.2.3. Distribution Channel breakdown size & forecasts, 2022-2032
8.2. Europe Opioid Induced Constipation (OIC) Drugs Market
8.2.1. U.K. Opioid Induced Constipation (OIC) Drugs Market
8.2.1.1. Drug Type breakdown size & forecasts, 2022-2032
8.2.1.2. Prescription Type breakdown size & forecasts, 2022-2032
8.2.1.3. Distribution Channel breakdown size & forecasts, 2022-2032
8.2.2. Germany Opioid Induced Constipation (OIC) Drugs Market
8.2.3. France Opioid Induced Constipation (OIC) Drugs Market
8.2.4. Spain Opioid Induced Constipation (OIC) Drugs Market
8.2.5. Italy Opioid Induced Constipation (OIC) Drugs Market
8.2.6. Rest of Europe Opioid Induced Constipation (OIC) Drugs Market
8.3. Asia-Pacific Opioid Induced Constipation (OIC) Drugs Market
8.3.1. China Opioid Induced Constipation (OIC) Drugs Market
8.3.1.1. Drug Type breakdown size & forecasts, 2022-2032
8.3.1.2. Prescription Type breakdown size & forecasts, 2022-2032
8.3.1.3. Distribution Channel breakdown size & forecasts, 2022-2032
8.3.2. India Opioid Induced Constipation (OIC) Drugs Market
8.3.3. Japan Opioid Induced Constipation (OIC) Drugs Market
8.3.4. Australia Opioid Induced Constipation (OIC) Drugs Market
8.3.5. South Korea Opioid Induced Constipation (OIC) Drugs Market
8.3.6. Rest of Asia Pacific Opioid Induced Constipation (OIC) Drugs Market
8.4. Latin America Opioid Induced Constipation (OIC) Drugs Market
8.4.1. Brazil Opioid Induced Constipation (OIC) Drugs Market
8.4.2. Mexico Opioid Induced Constipation (OIC) Drugs Market
8.4.3. Rest of Latin America Opioid Induced Constipation (OIC) Drugs Market
8.5. Middle East & Africa Opioid Induced Constipation (OIC) Drugs Market
8.5.1. Saudi Arabia Opioid Induced Constipation (OIC) Drugs Market
8.5.2. South Africa Opioid Induced Constipation (OIC) Drugs Market
8.5.3. Rest of Middle East & Africa Opioid Induced Constipation (OIC) Drugs Market
Chapter 9. Competitive Intelligence
9.1. Key Company SWOT Analysis
9.2. Top Market Strategies
9.3. Company Profiles
9.3.1. AstraZeneca
9.3.1.1. Key Information
9.3.1.2. Overview
9.3.1.3. Financial (Subject to Data Availability)
9.3.1.4. Product Summary
9.3.1.5. Market Strategies
9.3.2. Bausch Health Companies Inc.
9.3.3. Shionogi & Co., Ltd.
9.3.4. Cosmo Pharmaceuticals
9.3.5. Dr. Reddy's Laboratories Ltd.
9.3.6. Mallinckrodt plc
9.3.7. Merck & Co., Inc.
9.3.8. Novartis AG
9.3.9. Takeda Pharmaceutical Company Limited
9.3.10. Teva Pharmaceutical Industries Ltd.
9.3.11. RedHill Biopharma Ltd.
9.3.12. Sandoz (Novartis AG)
9.3.13. Daiichi Sankyo Co., Ltd.
9.3.14. Pfizer Inc.
9.3.15. Bayer AG
Chapter 10. Research Process
10.1. Research Process
10.1.1. Data Mining
10.1.2. Analysis
10.1.3. Market Estimation
10.1.4. Validation
10.1.5. Publishing
10.2. Research Attributes